- Home
- ALGS vs SDST Comparison
ALGS vs SDST Comparison
Compare ALGS & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- SDST
- Stock Information
- Founded
- ALGS 2018
- SDST 2022
- Country
- ALGS United States
- SDST United States
- Employees
- ALGS N/A
- SDST N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- SDST Blank Checks
- Sector
- ALGS Health Care
- SDST Finance
- Exchange
- ALGS Nasdaq
- SDST Nasdaq
- Market Cap
- ALGS 36.0M
- SDST 33.1M
- IPO Year
- ALGS 2020
- SDST N/A
- Fundamental
- Price
- ALGS $5.29
- SDST $0.62
- Analyst Decision
- ALGS Strong Buy
- SDST Buy
- Analyst Count
- ALGS 1
- SDST 2
- Target Price
- ALGS $70.00
- SDST $1.70
- AVG Volume (30 Days)
- ALGS 163.7K
- SDST 959.2K
- Earning Date
- ALGS 05-06-2025
- SDST 05-14-2025
- Dividend Yield
- ALGS N/A
- SDST N/A
- EPS Growth
- ALGS N/A
- SDST N/A
- EPS
- ALGS N/A
- SDST N/A
- Revenue
- ALGS $3,270,000.00
- SDST N/A
- Revenue This Year
- ALGS N/A
- SDST $4,114.37
- Revenue Next Year
- ALGS N/A
- SDST N/A
- P/E Ratio
- ALGS N/A
- SDST N/A
- Revenue Growth
- ALGS N/A
- SDST N/A
- 52 Week Low
- ALGS $3.76
- SDST $0.41
- 52 Week High
- ALGS $46.80
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- ALGS 43.20
- SDST N/A
- Support Level
- ALGS $5.47
- SDST N/A
- Resistance Level
- ALGS $6.12
- SDST N/A
- Average True Range (ATR)
- ALGS 0.60
- SDST 0.00
- MACD
- ALGS 0.12
- SDST 0.00
- Stochastic Oscillator
- ALGS 37.30
- SDST 0.00
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).